Abstract

Premature ejaculation, also referred to as rapid or early ejaculation, is a poorly understood disorder with no single, widely-recognised, evidence-based definition. Studies based on patient self-reporting indicate that premature ejaculation is a common complaint with estimated prevalence ranging from 4%–39% of men in the general community.¹ However, a lack of an accurate validated definition has made comparison of the results of such studies difficult.² In addition, perception of normal ejaculatory latency varies by country and differs when assessed by the patient or their partner.³ ▼Dapoxetine (Priligy—A. Menarini Farmaceutica Internazionale SRL), a short-acting selective serotonin reuptake inhibitor (SSRI) is the first drug to be licensed in the UK for on-demand management of diagnosed premature ejaculation.⁴ In this article we review the evidence for dapoxetine and discuss some of the challenges associated with its introduction.